PD-1/PD-L1 pathway in breast cancer
The programmed cell death-1 receptor (PD-1) is an immune checkpoint inhibitor which is expressed on the surface of immune effector cells. It is activated mainly by PD-L1 which can be expressed by all human cells. The PD-1/PD-L1 pathway plays a subtle role in maintaining peripheral T-lymphocyte toler...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
March 27, 2017
|
| In: |
Oncology research and treatment
Year: 2017, Jahrgang: 40, Heft: 5, Pages: 294-297 |
| ISSN: | 2296-5262 |
| DOI: | 10.1159/000464353 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1159/000464353 Verlag, Volltext: https://www.karger.com/Article/FullText/464353 
|
| Verfasserangaben: | Florian Schütz, Stefan Stefanovic, Luisa Mayer, Alexandra von Au, Christoph Domschke, Christof Sohn |
| Zusammenfassung: | The programmed cell death-1 receptor (PD-1) is an immune checkpoint inhibitor which is expressed on the surface of immune effector cells. It is activated mainly by PD-L1 which can be expressed by all human cells. The PD-1/PD-L1 pathway plays a subtle role in maintaining peripheral T-lymphocyte tolerance and regulating inflammation. In cancer, the expression of PD-L1 seems to be one of the major immune escape mechanisms. Many studies have shown efficacy of blocking PD-1 or PD-L1 with specific antibodies like pembrolizumab or atezulizumab. In breast cancer, potential response was demonstrated in metastatic triple-negative breast cancers. |
|---|---|
| Beschreibung: | Gesehen am 20.04.2018 |
| Beschreibung: | Online Resource |
| ISSN: | 2296-5262 |
| DOI: | 10.1159/000464353 |